Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

948 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
Okin PM, Wright JT, Nieminen MS, Jern S, Taylor AL, Phillips R, Papademetriou V, Clark LT, Ofili EO, Randall OS, Oikarinen L, Viitasalo M, Toivonen L, Julius S, Dahlöf B, Devereux RB. Okin PM, et al. Among authors: devereux rb. Am J Hypertens. 2002 Aug;15(8):663-71. doi: 10.1016/s0895-7061(02)02945-x. Am J Hypertens. 2002. PMID: 12160187
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H; LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Kjeldsen SE, et al. Among authors: devereux rb. JAMA. 2002 Sep 25;288(12):1491-8. doi: 10.1001/jama.288.12.1491. JAMA. 2002. PMID: 12243636 Clinical Trial.
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B; Losartan Intervention for Endpoint reduction in hypertension Study Investigations. Okin PM, et al. Among authors: devereux rb. Circulation. 2003 Aug 12;108(6):684-90. doi: 10.1161/01.CIR.0000083724.28630.C3. Epub 2003 Jul 28. Circulation. 2003. PMID: 12885747 Clinical Trial.
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B; LIFE Study Investigators. Okin PM, et al. Among authors: devereux rb. JAMA. 2004 Nov 17;292(19):2343-9. doi: 10.1001/jama.292.19.2343. JAMA. 2004. PMID: 15547161 Clinical Trial.
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB. Wachtell K, et al. Among authors: devereux rb. J Am Coll Cardiol. 2005 Mar 1;45(5):705-11. doi: 10.1016/j.jacc.2004.06.080. J Am Coll Cardiol. 2005. PMID: 15734614 Free article. Clinical Trial.
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB. Wachtell K, et al. Among authors: devereux rb. J Am Coll Cardiol. 2005 Mar 1;45(5):712-9. doi: 10.1016/j.jacc.2004.10.068. J Am Coll Cardiol. 2005. PMID: 15734615 Free article. Clinical Trial.
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
Fossum E, Moan A, Kjeldsen SE, Devereux RB, Julius S, Snapinn SM, Edelman JM, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Dahlöf B; LIFE Study Group. Fossum E, et al. Among authors: devereux rb. J Am Coll Cardiol. 2005 Sep 6;46(5):770-5. doi: 10.1016/j.jacc.2005.05.060. J Am Coll Cardiol. 2005. PMID: 16139123 Free article. Clinical Trial.
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, Dahlöf B; LIFE Study Investigators. Okin PM, et al. Among authors: devereux rb. Circulation. 2006 Mar 28;113(12):1588-96. doi: 10.1161/CIRCULATIONAHA.105.574822. Epub 2006 Mar 13. Circulation. 2006. PMID: 16534012 Clinical Trial.
Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
Smebye ML, Iversen EK, Høieggen A, Flaa A, Os I, Kjeldsen SE, Olsen MH, Chattopadhyay A, Hille DA, Lyle PA, Devereux RB, Dahlöf B. Smebye ML, et al. Among authors: devereux rb. Am J Cardiol. 2007 Sep 1;100(5):855-9. doi: 10.1016/j.amjcard.2007.03.109. Epub 2007 Jul 2. Am J Cardiol. 2007. PMID: 17719333 Free article. Clinical Trial.
948 results